Abstract:A novel series of peptidomimetic aldehydes was designed and synthesized to target 3C protease (3Cpro) of enterovirus 71 (EV71). Most of the compounds exhibited high antiviral activity, and among them, compound 18p demonstrated potent enzyme inhibitory activity and broad-spectrum antiviral activity on a panel of enteroviruses and rhinoviruses. The crystal structure of EV71 3Cpro in complex with 18p determined at a resolution of 1.2 Å revealed that 18p covalently linked to the catalytic Cys147 with an aldehyde group. In addition, these compounds also exhibited good inhibitory activity against the 3CLpro and the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially compound 18p (IC50 = 0.034 μM, EC50 = 0.29 μM). According to our previous work, these compounds have no reasons for concern regarding acute toxicity. Compared with AG7088, compound 18p also exhibited good pharmacokinetic properties and more potent anticoronavirus activity, making it an excellent lead for further development.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02258?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02258</a>.An overlay of EV71 3Cpro-18p and AG7088 complex structures; the binding pocket of 3Cpro of CoXB3, RV-A02, and EV71; the anti-SARS-CoV-2 activities of compounds; the 1H NMR and 13C NMR spectra of target compounds; the purity of target compounds; and the crystallography data collection and refinement statistics (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02258/suppl_file/jm0c02258_si_001.pdf">PDF</a>)Molecular formula stings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02258/suppl_file/jm0c02258_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Crystallographic fragment screen of Enterovirus D68 3C protease and iterative design of lead-like compounds using structure-guided expansions

Structure-Based Lead Optimization of Enterovirus D68 2A Protease Inhibitors

Crystallographic Fragment Screen of Coxsackievirus A16 2A Protease identifies new opportunities for the development of broad-spectrum anti-enterovirals

Elucidating the Substrate Envelope of Enterovirus 68-3C Protease: Structural Basis of Specificity and Potential Resistance

Pharmacological Characterization of the Mechanism of Action of R523062 , a Promising Antiviral for Enterovirus D68

Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2

Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein

Development of broad-spectrum enterovirus antivirals based on quinoline scaffold

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

Discovery and Optimization of Quinoline Analogues As Novel Potent Antivirals Against Enterovirus D68

Development of Enterovirus Antiviral Agents That Target the Viral 2C Protein

Fragment-wise Design of Inhibitors to 3C Proteinase from Enterovirus 71

Acrylamide fragment inhibitors that induce unprecedented conformational distortions in enterovirus 71 3C and SARS-CoV-2 main protease

Efficacy of an isoxazole-3-carboxamide analog of pleconaril in mouse models of Enterovirus-D68 and Coxsackie B5

Identifying novel chemical matter against the Chikungunya virus nsP3 macrodomain through crystallographic fragment screening

Identification of a cell-active chikungunya virus nsP2 protease inhibitor using a covalent fragment-based screening approach

Structure-based Discovery of Antiviral Inhibitors Targeting the E Dimer Interface of Japanese Encephalitis Virus.

Chemical Evolution of Antivirals Against Enterovirus D68 through Protein-Templated Knoevenagel Reactions

Discovery of a cell-active chikungunya virus nsP2 protease inhibitor using a covalent fragment-based screening approach

Crystallographic fragment screening delivers diverse chemical scaffolds for Zika virus NS2B-NS3 protease inhibitor development